Advertisement

Multimodal Management of Testicular Mesothelioma - A Retrospective Analysis From a Tertiary Cancer Care Centre

Published:September 10, 2022DOI:https://doi.org/10.1016/j.clgc.2022.09.001

      Abstract

      The main modality of management of paratesticular mesothelioma remains orchiectomy while the use of adjuvant chemotherapy has not yet been explored. We aim to analyse the outcome of the multimodal management protocol in testicular mesothelioma We conducted a retrospective analysis of patients registered and treated for testicular mesothelioma between 2009 and 2019 in an oncology tertiary care hospital. Patients presenting with nodal, metastatic disease were treated with adjuvant, palliative chemotherapy respectively and their response to treatment was periodically monitored. Eight patients (3 early, 1 nodal, 4 metastatic) with median age of 58 years was included in the study. Patients who had limited (early, nodal) disease (n = 4) had overall survival ranging from 20 to 140 months while metastatic disease (n = 4) had poor outcomes with overall survival ranging from 2 to 13 months. Surgery remains to be an important modality of therapy that improves the local control and overall outcomes and the quality of life even in patients with metastatic disease at the time of diagnosis. Adjuvant chemotherapy might play a role in effective management of locoregional disease. The performance status, the extent of disease at the time of presentation are the important prognostic factors in deciding the outcome of the disease management.

      Keywords

      Abbreviations:

      PET (Positron emission tomography), CECT (Contrast-enhanced computed tomography), AFP (Alpha-fetoprotein), HCG (Human chorionic gonadotropin), LDH (Lactate dehydrogenase)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Drevinskaite M
        • Patasius A
        • Kevlicius L
        • Mickys U
        • Smailyte G.
        Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
        BMC Cancer. 2020; 20: 162https://doi.org/10.1186/s12885-020-6648-3
        • Kim RY
        • Sterman DH
        • Haas AR.
        Malignant mesothelioma: has anything changed?.
        Semin Respir Crit Care Med. 2019; 40: 347-360https://doi.org/10.1055/s-0039-1693406
        • Mezei G
        • Chang ET
        • Mowat FS
        • Moolgavkar SH.
        Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis.
        Ann Epidemiol. 2017; 27 (e11): 348-359https://doi.org/10.1016/j.annepidem.2017.04.001
        • Plas E
        • Riedl CR
        • Pflüger H.
        Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters.
        Cancer. 1998; 83: 2437-2446https://doi.org/10.1002/(sici)1097-0142(19981215)83:12<2437::aid-cncr6>3.0.co;2-g
        • Serio G
        • Ceppi M
        • Fonte A
        • Martinazzi M.
        Malignant mesothelioma of the testicular tunica vaginalis.
        Eur Urol. 1992; 21: 174-176https://doi.org/10.1159/000474830
        • Trenti E
        • Palermo SM
        • D'Elia C
        • et al.
        Malignant mesothelioma of tunica vaginalis testis: Report of a very rare case with review of the literature.
        Arch Ital Urol Androl. 2018; 90: 212-214https://doi.org/10.4081/aiua.2018.3.212
        • Bisceglia M
        • Dor DB
        • Carosi I
        • Vairo M
        • Pasquinelli G
        Paratesticular mesothelioma. Report of a case with comprehensive review of literature.
        Adv Anat Pathol. 2010; 17: 53-70https://doi.org/10.1097/PAP.0b013e3181c66fbc
        • Jean D
        • Jaurand MC.
        Causes and pathophysiology of malignant pleural mesothelioma.
        Lung Cancer Management. 2015; 4: 219-229https://doi.org/10.2217/lmt.15.21
        • Nazemi A
        • Nassiri N
        • Pearce S
        • Daneshmand S
        Testicular mesothelioma: an analysis of epidemiology, patient outcomes, and prognostic factors.
        Urology. 2019; 126: 140-144https://doi.org/10.1016/j.urology.2019.01.009
        • Bibby AC
        • Tsim S
        • Kanellakis N
        • et al.
        Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
        Eur Respir Rev. 2016; 25: 472-486https://doi.org/10.1183/16000617.0063-2016
        • Andresen ED
        • Henning G
        • Uhlman MA
        • Gupta A.
        Malignant mesothelioma of the tunica vaginalis: a rare case report and description of multimodal treatment.
        Can J Urol. 2016; 23: 8585-8589
        • Chekol SS
        • Sun CC.
        Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis.
        Arch Pathol Lab Med. 2012; 136: 113-117https://doi.org/10.5858/arpa.2010-0550-RS
        • Mancuso P
        • Murphy MJ
        • Barry F.
        Immunomodulatory effect of mesenchymal stem cells following intra-articular injection in a model of osteoarthritis: a potential role for apoptosis.
        Osteoarthritis and Cartilage. 2017; 25: S386-S387https://doi.org/10.1016/j.joca.2017.02.663
        • Brun C
        • Giusiano S
        • Thiam K
        • Guinde J
        • Froudarakis M
        • Astoul P.
        The necessity of a more aggressive initial surgical treatment in patients with mesothelioma of the testicular tunica vaginalis.
        Ann Med Surg (Lond). 2019; 47: 57-60https://doi.org/10.1016/j.amsu.2019.10.012
        • da Fonseca LG
        • Marques DF
        • Takahashi TK
        • Aguiar FN
        • Ravanini JN
        • Saragiotto DF.
        Malignant paratesticular mesothelioma.
        Autops Case Rep. 2014; 4: 45-51https://doi.org/10.4322/acr.2014.007